Bladder Cancer News and Research

Latest Bladder Cancer News and Research

European Urology Forum to be held in Switzerland

The Urology Forum stands out from other meetings because it not only deals with pertinent academic topics but also takes place in a relaxed environment where people can thoroughly examine the information that is presented.

9 Feb 2010

Study: Medicare bladder cancer treatment policy raises health costs

Reuters: "Medicare's move in 2005 to pay doctors to do bladder cancer surgery in their offices rather than in hospitals dramatically raised the number of procedures and overall health costs, U.S. researchers said on Monday.

9 Feb 2010

Increased Medicare reimbursement leads to rise in outpatient bladder cancer surgeries

Increased Medicare payments to physicians for outpatient surgeries for bladder cancer have led to a dramatic rise in the number of these procedures being performed and an overall increase in cost to the healthcare system. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The findings indicate that some Medicare policies aimed at decreasing costs may instead be contributing to an increase in healthcare expenditures.

8 Feb 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.

13 Jan 2010

OncoDiagnostic Laboratory acquired by Predictive Biosciences

Predictive Biosciences today announced that it has acquired Cleveland, Ohio based OncoDiagnostic Laboratory (“ODL”), a private, Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians nationwide.

7 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

U.S. market for urological devices to reach over $5.4 billion in 2016

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.

6 Jan 2010

Rosetta Genomics announces third-quarter 2009 financial results

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2009 and provided a business update.

18 Dec 2009

Genetic variations in Sonic Hedgehog pathway associated with response to standard immunotherapy

Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer, scientists from The University of Texas M. D. Anderson Cancer Center reported today at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

10 Dec 2009

Novel multi-analyte approach to develop urine-biomarker based diagnostic assay to be presented

Predictive Biosciences today announced that Company scientists will be presenting a novel multi-analyte approach to the development of a non-invasive, urine-biomarker based diagnostic assay during the 10th Annual Meeting of the Society of Urologic Oncology (SUO).

3 Dec 2009

TARIS Biomedical completes Phase 1 study of its intravesical drug-device convergence system

TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, announced today the successful completion of a Phase 1 clinical study of its intravesical drug-device convergence system designed to provide sustained-release of drug directly to the bladder.

2 Dec 2009

Uninsured cancer patient gives human face to health care debate

The Sacramento Bee has a three-part profile of an uninsured cancer patient, which is tracked alongside the progressing health care reform debate.

1 Dec 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents in Japan for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition.

25 Nov 2009

Spectrum Pharmaceuticals, Handok Pharmaceuticals sign collaboration agreement

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.

23 Nov 2009

2nd EMUC Meeting to discuss urological cancer

Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level.

20 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Chinese SFDA approves China Medical Technologies' Leukemia BCR/ABL fusion gene detection FISH Probe

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its Leukemia BCR/ABL fusion gene detection FISH Probe (the "Leukemia BCR/ABL FISH Probe") from the State Food and Drug Administration of China (the "SFDA").

9 Nov 2009

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

6 Nov 2009

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

European Urology Forum to be held in Switzerland

Study: Medicare bladder cancer treatment policy raises health costs

Increased Medicare reimbursement leads to rise in outpatient bladder cancer surgeries

Global market for oncology drugs is forecast to reach $80 billion by 2050

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

OncoDiagnostic Laboratory acquired by Predictive Biosciences

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

U.S. market for urological devices to reach over $5.4 billion in 2016

Rosetta Genomics announces third-quarter 2009 financial results

Genetic variations in Sonic Hedgehog pathway associated with response to standard immunotherapy

Novel multi-analyte approach to develop urine-biomarker based diagnostic assay to be presented

TARIS Biomedical completes Phase 1 study of its intravesical drug-device convergence system

Uninsured cancer patient gives human face to health care debate

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Spectrum Pharmaceuticals, Handok Pharmaceuticals sign collaboration agreement

2nd EMUC Meeting to discuss urological cancer

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Chinese SFDA approves China Medical Technologies' Leukemia BCR/ABL fusion gene detection FISH Probe

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in